ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 301

Decreased Frequency of Dystrophic Calcifications in Children with Juvenile Dermatomyositis: A 10-Year Study

Lauren M. Pachman1, Gabrielle A. Morgan2, Megan L. Curran1, Lori J. Ferguson3 and Chiang-Ching Huang4, 1Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, 3Children's Hospital of Chicago Research Center, Cure JM Myositis Center, Chicago, IL, 4Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Calcinosis and juvenile dermatomyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: In Juvenile Dermatomyositis (JDM), dystrophic calcifications, associated with increased morbidity and mortality, have been reported for 20-30% of patients. There are few laboratory indicators of disease activity, and a duration of untreated disease (DUD) greater than 4.5 months is associated with normalization of muscle enzymes (CK, Aldolase, LDH, SGOT), commonly used to guide response to therapy. Objective: To determine the current frequency of dystrophic calcifications in children with JDM.

Methods: Patients with definite/probable JDM (overlap syndromes excluded) seen between 2000 and 2010 at the Ann and Robert H. Lurie Children’s Hospital enrolled (IRB #2012-12858).  At the first visit of 90 children, 52 were untreated and 38 were previously treated.  Demographic data were obtained (Table), and their clinical inflammation assessed by disease activity scores (DAS) for skin and muscle.  Diagnosis was confirmed by laboratory testing, and MRI directed muscle biopsy.

 

Untreated

(N=52)

Treated

(N=38)

P-value

White/Hispanic

(N, %)

46 (88%)

36 (95%)

0.51

Female

(N, %)

40 (77%)

28 (74%)

0.91

Age at onset

(year,mean±SD)

5.8±3.17

6.2±3.4

0.52

Disease duration

(month,mean±SD)

10.4±16.2

9.6±13.4

0.79

DAS skin

(mean±SD)

5.8±1.3

4.9±2.3

0.055

DAS muscle

(mean±SD)

4.0±2.6

4.1±2.8

0.91

Results: Of the 52 untreated patients, 5 (9.6%) had calcinosis at presentation. The 52 children were initially treated with oral prednisone (47), IV prednisone (45), methotrexate (48), hydroxychloroquine (11), cyclosporin (1), mycophenolate (2), IVIG (0), and alendronate (0).  During their disease course, the following medications were used: oral prednisone (50), IV methlyprednisone (45), methotrexate (48), hydroxychloroquine (21), cyclosporin (10), mycophenolate (29), IVIG (6), and alendronate (0).  At follow-up 4/5 of the children’s calcifications had resolved and the fifth one had diminished in size. None of the children with initially untreated JDM developed new calcifications. Of the 38 children previously treated, 7 (18%) had calcifications.  Medications taken: oral prednisone (25), IV methylprednisone (5), methotrexate (25), hydroxychloroquine (20), cyclosporin (3), mycophenolate (2), IVIG (5), and alendronate (2).  At follow-up, of the 7 children with calcifications:  2 improved in size (1 totally resolved), 3 remained the same, one developed more advanced calcification (from moderate to severe), and one developed 36 deposits months later.

Conclusion: In untreated JDM without calcifications, no deposits developed during a mean follow-up period of <4 years. Of the 5 untreated JDM with calcifications, 4/5 resolved and the one diminished. Of the seven treated JDM referred with calcifications, only one totally resolved, and one developed new calcifications after 36 months of therapy. These data suggest that early immunosuppressive therapy may impair the development of dystrophic calcifications in JDM, for only 7.0% of this total group had calcifications. None of the 52 initially untreated children without calcifications developed them at a later time.  We speculate that dystrophic calcifications in JDM are preventable.


Disclosure:

L. M. Pachman,

NIH- R0-1 ; Education grant from Behring for $5,000,

2;

G. A. Morgan,
None;

M. L. Curran,
None;

L. J. Ferguson,
None;

C. C. Huang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-frequency-of-dystrophic-calcifications-in-children-with-juvenile-dermatomyositis-a-10-year-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology